CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 24 enrolled
Drug / intervention
Methylphenidate +1 moredrug
Likely dose
Methylphenidate 20mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01896700
NCT01896700Phase 3Completed
CompareCT.gov

Methylphenidate to Improve Balance and Walking in MS

Oregon Health and Science University·interventional·Posted Jul 11, 2013·Updated Apr 5, 2018

In Brief

A Phase 3 clinical trial evaluating Methylphenidate and Placebo for Multiple Sclerosis. Completed, enrolled 24 participants across 1 site.

Detailed Summary

Methylphenidate is an amphetamine-like psychomotor stimulant drug currently approved for the treatment of attention-deficit hyperactivity disorder (ADHD), postural orthostasis tachycardia syndrome and narcolepsy. It is also often prescribed off label to people with MS to improve fatigue. It is proposed that methylphenidate may also improve imbalance and walking deficits in MS by improving concentration and central integration, one of the primary mechanisms thought to underlie imbalance and walking deficits in MS.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesUnited States
CollaboratorsPortland VA Medical Center

Timeline

Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 11, 2013
Enrollment StartJul 1, 2013
Primary CompletionApr 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 13.0 years ago

Interventions

Methylphenidatedrug

Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each

Placebodrug

Escalating matched dose of placebo